Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Vaccines

  Free Subscription


05.07.2021

3 Ann Intern Med
1 Arch Virol
1 BMC Pediatr
9 BMJ
2 Clin Infect Dis
1 J Immunol
2 J Infect
2 J Infect Dis
3 JAMA
3 Lancet
4 N Engl J Med
3 Nat Med
2 Pediatrics
1 PLoS Med
4 PLoS One
1 Proc Natl Acad Sci U S A
1 Science
30 Vaccine
1 Virology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Intern Med

  1. SANGLI S, Virani A, Cheronis N, Vannatter B, et al
    Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine.
    Ann Intern Med. 2021 Jun 29. doi: 10.7326/L21-0244.
    PubMed        

  2. LAVANGE L, Adam SJ, Currier JS, Higgs ES, et al
    Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics.
    Ann Intern Med. 2021 Jun 29. doi: 10.7326/M21-1269.
    PubMed         Abstract available

  3. PISHKO AM, Cuker A
    Thrombosis After Vaccination With Messenger RNA-1273: Is This Vaccine-Induced Thrombosis and Thrombocytopenia or Thrombosis With Thrombocytopenia Syndrome?
    Ann Intern Med. 2021 Jun 29. doi: 10.7326/M21-2680.
    PubMed        


    Arch Virol

  4. UPRETY T, Wang D, Li F
    Recent advances in rotavirus reverse genetics and its utilization in basic research and vaccine development.
    Arch Virol. 2021 Jul 3. pii: 10.1007/s00705-021-05142.
    PubMed         Abstract available


    BMC Pediatr

  5. MULLER-NORDHORN J, Neumann K, Keil T, Willich SN, et al
    State-level trends in sudden unexpected infant death and immunization in the United States: an ecological study.
    BMC Pediatr. 2021;21:274.
    PubMed         Abstract available


    BMJ

  6. WISE J
    Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines?
    BMJ. 2021;373:n1635.
    PubMed        

  7. TEERAWATTANANON Y, Teo YY, Lim JFY, Hsu LY, et al
    Vaccinating undocumented migrants against covid-19.
    BMJ. 2021;373:n1608.
    PubMed        

  8. TANNE JH
    Covid-19: US doctors suggest new ways to target vaccine hesitancy.
    BMJ. 2021;373:n1640.
    PubMed        

  9. MAHASE E
    Covid-19: Third vaccine dose boosts immune response but may not be needed, say researchers.
    BMJ. 2021;373:n1659.
    PubMed        

  10. STOKEL-WALKER C
    Covid-19: The countries that have mandatory vaccination for health workers.
    BMJ. 2021;373:n1645.
    PubMed        

  11. RIMMER A
    Covid-19: GP staff have faced threats and abuse during vaccination programme, poll finds.
    BMJ. 2021;373:n1665.
    PubMed        

  12. MAHASE E
    Covid-19: Pfizer vaccine could provide lasting immunity, small study suggests.
    BMJ. 2021;374:n1675.
    PubMed        

  13. GRIFFIN S
    Covid-19: Millions could be offered booster vaccinations from September.
    BMJ. 2021;374:n1686.
    PubMed        

  14. GREEN ST
    Recognising the value of "shared pain"-mandatory covid-19 vaccination should include all NHS workers.
    BMJ. 2021;374:n1668.
    PubMed        


    Clin Infect Dis

  15. ANDREJKO K, Whittles LK, Lewnard JA
    Health-economic value of vaccination against group A Streptococcus in the United States.
    Clin Infect Dis. 2021 Jun 30. pii: 6311854. doi: 10.1093.
    PubMed         Abstract available

  16. LUMLEY SF, Rodger G, Constantinides B, Sanderson N, et al
    An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status.
    Clin Infect Dis. 2021 Jul 3. pii: 6314286. doi: 10.1093.
    PubMed         Abstract available


    J Immunol

  17. MATCHETT WE, Joag V, Stolley JM, Shepherd FK, et al
    Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity.
    J Immunol. 2021 Jun 30. pii: jimmunol.2100421. doi: 10.4049/jimmunol.2100421.
    PubMed         Abstract available


    J Infect

  18. HSU L, Wisplinghoff H, Kossow A, Hurrass J, et al
    Limited protection against SARS-CoV-2 infection and virus transmission after mRNA vaccination.
    J Infect. 2021 Jun 29. pii: S0163-4453(21)00320.
    PubMed        

  19. SALVAGNO GL, Henry BM, Pighi L, De Nitto S, et al
    Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers.
    J Infect. 2021 Jun 29. pii: S0163-4453(21)00321.
    PubMed        


    J Infect Dis

  20. GIACOMELLI CAO R, Christian L, Xu Z, Jaramillo L, et al
    Early changes in interferon gene expression and antibody responses following influenza vaccination in pregnant women.
    J Infect Dis. 2021 Jul 1. pii: 6312681. doi: 10.1093.
    PubMed         Abstract available

  21. HUANG Y, Williamson BD, Moodie Z, Carpp LN, et al
    Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials.
    J Infect Dis. 2021 Jun 26. pii: 6310132. doi: 10.1093.
    PubMed         Abstract available


    JAMA

  22. PERSAD G, Emanuel EJ
    Ethical Considerations of Offering Benefits to COVID-19 Vaccine Recipients.
    JAMA. 2021 Jul 1. pii: 2781755. doi: 10.1001/jama.2021.11045.
    PubMed        

  23. KAVANAGH MM, Gostin LO, Sunder M
    Sharing Technology and Vaccine Doses to Address Global Vaccine Inequity and End the COVID-19 Pandemic.
    JAMA. 2021 Jul 1. pii: 2781756. doi: 10.1001/jama.2021.10823.
    PubMed        

  24. WALKEY AJ, Law A, Bosch NA
    Lottery-Based Incentive in Ohio and COVID-19 Vaccination Rates.
    JAMA. 2021 Jul 2. pii: 2781792. doi: 10.1001/jama.2021.11048.
    PubMed        


    Lancet

  25. SMITH MJ
    What constitutes success in the roll-out of COVID-19 vaccines?
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01244.
    PubMed        

  26. DUARTE-SALLES T, Prieto-Alhambra D
    Heterologous vaccine regimens against COVID-19.
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01442.
    PubMed        

  27. THE LANCET
    Protecting refugees during the COVID-19 pandemic.
    Lancet. 2021;397:2309.
    PubMed        


    N Engl J Med

  28. LUSTIG Y, Nemet I, Kliker L, Zuckerman N, et al
    Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2.
    N Engl J Med. 2021 Apr 7. doi: 10.1056/NEJMc2104036.
    PubMed        

  29. HEATH PT, Galiza EP, Baxter DN, Boffito M, et al
    Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
    N Engl J Med. 2021 Jun 30. doi: 10.1056/NEJMoa2107659.
    PubMed         Abstract available

  30. THOMPSON MG, Burgess JL, Naleway AL, Tyner H, et al
    Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2021 Jun 30. doi: 10.1056/NEJMoa2107058.
    PubMed         Abstract available

  31. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Another New Covid-19 Vaccine.
    N Engl J Med. 2021;385:e13.
    PubMed        


    Nat Med

  32. O'LEARY K
    Building a pandemic-proof vaccine.
    Nat Med. 2021 Jun 28. pii: 10.1038/d41591-021-00042.
    PubMed        

  33. SALJE H, Alera MT, Chua MN, Hunsawong T, et al
    Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection.
    Nat Med. 2021 Jun 24. pii: 10.1038/s41591-021-01392.
    PubMed         Abstract available

  34. ROSSMAN H, Shilo S, Meir T, Gorfine M, et al
    COVID-19 dynamics after a national immunization program in Israel.
    Nat Med. 2021;27:1055-1061.
    PubMed         Abstract available


    Pediatrics


  35. Recommended Childhood and Adolescent Immunization Schedule: United States, 2021.
    Pediatrics. 2021;147.
    PubMed        

  36. KONERU A, Fenlon N, Schillie S, Williams C, et al
    National Perinatal Hepatitis B Prevention Program: 2009-2017.
    Pediatrics. 2021 Feb 2. pii: peds.2020-1823. doi: 10.1542/peds.2020-1823.
    PubMed         Abstract available


    PLoS Med

  37. ISANAKA S, Langendorf C, McNeal MM, Meyer N, et al
    Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: Extended follow-up of a randomized controlled trial.
    PLoS Med. 2021;18:e1003655.
    PubMed         Abstract available


    PLoS One

  38. DUTTA T, Agley J, Meyerson BE, Barnes PA, et al
    Perceived enablers and barriers of community engagement for vaccination in India: Using socioecological analysis.
    PLoS One. 2021;16:e0253318.
    PubMed         Abstract available

  39. THANEE C, Kittikraisak W, Sinthuwattanawibool C, Roekworachai K, et al
    Knowledge, attitude/perception, and practice related to seasonal influenza vaccination among caregivers of young Thai children: A cross-sectional study.
    PLoS One. 2021;16:e0253561.
    PubMed         Abstract available

  40. RUJUMBA J, Akugizibwe M, Basta NE, Banura C, et al
    Why don't adolescent girls in a rural Uganda district initiate or complete routine 2-dose HPV vaccine series: Perspectives of adolescent girls, their caregivers, healthcare workers, community health workers and teachers.
    PLoS One. 2021;16:e0253735.
    PubMed         Abstract available

  41. MCKUNE S, Serra R, Toure A
    Gender and intersectional analysis of livestock vaccine value chains in Kaffrine, Senegal.
    PLoS One. 2021;16:e0252045.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  42. WANG Y, Yang C, Song Y, Coleman JR, et al
    Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available


    Science

  43. MARTINEZ DR, Schafer A, Leist SR, De la Cruz G, et al
    Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice.
    Science. 2021 Jun 22. pii: science.abi4506. doi: 10.1126/science.abi4506.
    PubMed         Abstract available


    Vaccine

  44. BROWN CC, Young SG, Pro GC
    COVID-19 vaccination rates vary by community vulnerability: A county-level analysis.
    Vaccine. 2021 Jun 17. pii: S0264-410X(21)00774.
    PubMed         Abstract available

  45. ZIMMERMAN RK
    Helping patients with ethical concerns about COVID-19 vaccines in light of fetal cell lines used in some COVID-19 vaccines.
    Vaccine. 2021 Jun 15. pii: S0264-410X(21)00763.
    PubMed         Abstract available

  46. FOGEL B, Schaefer EW, Hicks SD
    Early influenza vaccination rates decline in children during the COVID-19 pandemic.
    Vaccine. 2021 Jun 17. pii: S0264-410X(21)00777.
    PubMed         Abstract available

  47. OOSTDIJK C, Van Zoonen K, Ruijs WLM, Mollema L, et al
    Household decision-making for the MenACWY vaccination: How parents and adolescents deal with an adolescent vaccination decision.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00772.
    PubMed         Abstract available

  48. PHILLIP K, Nair N, Samanta K, Azevedo JF, et al
    Maternal transfer of neutralizing antibodies to B. burgdorferi OspA after oral vaccination of the rodent reservoir.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00761.
    PubMed         Abstract available

  49. KRISTENSEN D, Giersing B, Hickling J, Kazi F, et al
    A global collaboration to advance vaccine product innovations - The Vaccine Innovation Prioritisation Strategy.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00711.
    PubMed        

  50. POLAND GA, Ovsyannikova IG, Kennedy RB
    The need for broadly protective COVID-19 vaccines: Beyond S-only approaches.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00764.
    PubMed        

  51. RADHAKRISHNAN L, Stein Z, DeVies J, Smith A, et al
    Syndromic surveillance of vaccine-associated adverse events in U.S. emergency departments.
    Vaccine. 2021 Jun 21. pii: S0264-410X(21)00766.
    PubMed         Abstract available

  52. SMITH KJ, Wateska AR, Nowalk MP, Lin CJ, et al
    Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis.
    Vaccine. 2021 Jun 21. pii: S0264-410X(21)00773.
    PubMed         Abstract available

  53. KAUR R, Pham M, Pichichero M
    Serum antibody levels to pneumococcal polysaccharides 22F, 33F, 19A and 6A that correlate with protection from colonization and acute otitis media in children.
    Vaccine. 2021;39:3900-3906.
    PubMed         Abstract available

  54. KELLY SM, Larsen KR, Darling R, Petersen AC, et al
    Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against Bacillus anthracis.
    Vaccine. 2021;39:3862-3870.
    PubMed         Abstract available

  55. WANG Z, Zhou C, Gao F, Zhu Q, et al
    Preclinical evaluation of recombinant HFMD vaccine based on enterovirus 71 (EV71) virus-like particles (VLP): Immunogenicity, efficacy and toxicology.
    Vaccine. 2021 Jun 21. pii: S0264-410X(21)00767.
    PubMed         Abstract available

  56. MARTIN-MERINO E, Castillo-Cano B, Martin-Perez M, Llorente-Garcia A, et al
    Papillomavirus vaccination and Guillain-Barre Syndrome among girls: A cohort study in Spain.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00765.
    PubMed         Abstract available

  57. DESAI AP, Desai AP, Loomis GJ
    Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00808.
    PubMed         Abstract available

  58. OSTERGAARD L, Vesikari T, Senders SD, Flodmark CE, et al
    Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00717.
    PubMed         Abstract available

  59. PLUTZER E, Warner SB
    A potential new front in health communication to encourage vaccination: Health education teachers.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00800.
    PubMed         Abstract available

  60. VERGER P, Duale C, Lenzi N, Scronias D, et al
    Vaccine hesitancy among hospital staff physicians: A cross-sectional survey in France in 2019.
    Vaccine. 2021 Jun 28. pii: S0264-410X(21)00803.
    PubMed         Abstract available

  61. BALDOLLI A, Michon J, Appia F, Galimard C, et al
    Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00804.
    PubMed         Abstract available

  62. EARLE KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, et al
    Evidence for antibody as a protective correlate for COVID-19 vaccines.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00658.
    PubMed         Abstract available

  63. GESSNER BD, Theilacker C, Mendez C, Jodar L, et al
    Comment on "Vila-Corcoles et al., Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016."
    Vaccine. 2021;39:4032-4033.
    PubMed        

  64. BELLIER L, Petitjean A, Sarazu T, Tresierra J, et al
    Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
    Vaccine. 2021;39:4144-4152.
    PubMed         Abstract available

  65. BURNETT E, Juin S, Esona MD, Desormeaux AM, et al
    Effectiveness of monovalent rotavirus vaccine against hospitalizations due to all rotavirus and equine-like G3P[8] genotypes in Haiti 2014-2019.
    Vaccine. 2021 Jun 26. pii: S0264-410X(21)00805.
    PubMed         Abstract available

  66. DASSAH S, Adu B, Sirima SB, Mordmuller B, et al
    Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00760.
    PubMed         Abstract available

  67. FURUYA-KANAMORI L, Xu C, Doi SAR, Clark J, et al
    Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: A systematic review and network meta-analysis.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00759.
    PubMed         Abstract available

  68. TUO W, Feng X, Cao L, Vinyard B, et al
    Vaccination with Neospora caninum-cyclophilin and -profilin confers partial protection against experimental neosporosis-induced abortion in sheep.
    Vaccine. 2021 Jun 24. pii: S0264-410X(21)00768.
    PubMed         Abstract available

  69. CARNALLA M, Torres-Ibarra L, Barrientos-Gutierrez T, Cruz-Valdez A, et al
    Reduction of HPV16/18 prevalence in young women after eight years of three- and two-dose vaccination schemes.
    Vaccine. 2021 Jun 25. pii: S0264-410X(21)00776.
    PubMed         Abstract available

  70. FELIX S, Handem S, Nunes S, Paulo AC, et al
    Impact of private use of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal carriage among Portuguese children living in urban and rural regions.
    Vaccine. 2021 Jun 25. pii: S0264-410X(21)00771.
    PubMed         Abstract available

  71. SARHAN AT, Bahey-El-Din M, Zaghloul TI
    Recombinant Ax21 protein is a promising subunit vaccine candidate against Stenotrophomonas maltophilia in a murine infection model.
    Vaccine. 2021 Jun 26. pii: S0264-410X(21)00801.
    PubMed         Abstract available

  72. LUNDBERG L, Bygdell M, Stukat von Feilitzen G, Woxenius S, et al
    Recent MMR vaccination in health care workers and Covid-19: A test negative case-control study.
    Vaccine. 2021 Jun 22. pii: S0264-410X(21)00795.
    PubMed         Abstract available

  73. FISCHER P, Pawlowski A, Cao D, Bell D, et al
    Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00796.
    PubMed         Abstract available


    Virology

  74. KURT-JONES EA, Dudek TE, Watanabe D, Mandell L, et al
    Expression of SARS coronavirus 1 spike protein from a herpesviral vector induces innate immune signaling and neutralizing antibody responses.
    Virology. 2021;559:165-172.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: